Simultaneous Integrated Boost for Mediastinal Lymph Node Recurrence After Radical Surgery of Esophageal Cancer

  • End date
    Apr 30, 2022
  • participants needed
  • sponsor
    Ruijin Hospital
Updated on 22 January 2021
squamous cell carcinoma
esophageal cancer
esophagus cancer
squamous cell carcinoma of esophagus
kidney function test


Esophageal cancer (EC) ranks the seventh most diagnosed malignant tumor (572,000 new cases) and the sixth cancer-related mortality (509,000 deaths) worldwide in 2018. The incidence of EC is strikingly varying among the regions and sexes. Approximately 70% of EC cases occur in men, and there is a 2-fold to 3-fold difference in incidence and mortality rates between regions worldwide. According to the latest reported in 2017, esophageal cancer ranks the sixth most common cancer and the fourth leading cause of cancer-mortality in China. Currently, esophagectomy is considered as the standard treatment for resectable EC patients. However, the prognosis of stage IIA-III esophageal cancer after esophagectomy remains poor, and local regional lymph node recurrence is the major patterns of recurrence, and mediastinal lymph node recurrence is one of the most common sites. Previous retrospective study has found that salvage chemoradiotherapy is a effective treatment option for these patients. However, the optimal dose remains unknown. In addition, no prospective trials have been conducted to investigate the efficacy and toxicities of salvage chemo-radiotherapy by using simultaneous integrated boost for the treatment of mediastinal lymph node recurrence after radical surgery of esophageal Cancer

Condition Esophageal Diseases, Esophageal Cancer, head and neck cancer, Esophageal Carcinoma, Salvage Radiotherapy, Esophageal Disorders, Dose-escalation, Mediastinal Lymph Node Recurrence, Dose-escalation, Dose Escalation, esophagus cancer, oesophageal cancer, cancer of the esophagus, oesophageal carcinoma
Treatment treatment group(phase I), treatment group (phase II)
Clinical Study IdentifierNCT03990532
SponsorRuijin Hospital
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Histo-pathologically proven diagnosis of esophageal squamous cell carcinoma
Age 18 and 80 ECOG performance status 0-1. Clinical diagnosis of 5 mediastinal
lymph nodes recurrence after esophagectomy
Patients without distant metastasis and life expectancy 3 months. adequate
liver and renal function and adequate bone marrow reservation. Written, signed
informed consent

Exclusion Criteria

Prior radiotherapy to recurrence site of esophageal cancer. Other co-existing
malignancies or malignancies diagnosed within the last 5 years
Pregnant women. Women who are breastfeeding a baby. Patients with uncontrolled
serious medical or mental illnesses
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note